

ASX ANNOUNCEMENT

28 FEBRUARY 2024



First Polish *shipment*



Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") is pleased to announce that it has shipped its first batch of LGP-branded high-THC Desert Flame cannabis flower products to Poland.

The shipment is the culmination of an over three-year process which included obtaining a Polish Marketing Authorisation from the Polish health regulator, with the products to be distributed in Poland by LGP's distribution partner, Medezin. See ASX announcement dated 2 August 2023 for further details in relation to LGP's Polish market engagement: [Desert-Flame-granted-Polish-Marketing-Authorisation.pdf](https://investor.littlegreenpharma.com/Desert-Flame-granted-Polish-Marketing-Authorisation.pdf) (investor.littlegreenpharma.com)

The Polish cannabis market is currently serviced by less than 10 suppliers, predominantly large North American suppliers such as Curaleaf, Aurora, Canopy Growth and Tilray, with LGP being the first Australian company in market. With a population of 38 million, an import only supply regime, general practitioner prescribing capability, no restrictions on the conditions treatable with cannabis, and a predicted compound annual growth rate (CAGR) of 16%¹, LGP regards Poland as a highly prospective new medicinal cannabis market in Europe alongside France and Italy.

ENDS

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Alistair Warren".

Alistair Warren

Company Secretary

1. <https://www.statista.com/outlook/hmo/cannabis/medical-cannabis/poland>

For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: a.warren@lgp.global
T: +618 6280 0050

Paul Long
Chief Executive Officer

Little Green Pharma
E: p.long@lgp.global
T: +618 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomass per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp